Kura Oncology, Inc.
NASDAQTotal Valuation
Kura Oncology, Inc. carries a market capitalization of 964.09M, placing it among publicly traded companies globally. Its enterprise value stands at 481.26M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 964.09M |
| Enterprise Value | 481.26M |
Share Statistics
Kura Oncology, Inc. currently has 88.95M shares outstanding.
| Shares Outstanding | 88.95M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12.54, and the price-to-book ratio stands at 20.15.
| PE Ratio | N/A |
| PS Ratio | 12.54 |
| PB Ratio | 20.15 |
| P/TBV Ratio | 20.15 |
| P/FCF Ratio | -9.13 |
| P/OCF Ratio | -8.67 |
Enterprise Valuation
| EV / Sales | 6.23 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 2.58 |
Financial Position
Kura Oncology, Inc. maintains a current ratio of 4.73, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 50.49, indicating elevated leverage, while an interest coverage ratio of -223.10 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.73 |
| Quick Ratio | 4.47 |
| Debt / Equity | 50.49 |
| Debt / EBITDA | -0.08 |
| Interest Coverage | -223.10 |
Financial Efficiency
| Return on Equity (ROE) | -167.71 |
| Return on Assets (ROA) | -46.73 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.41 |
Taxes
| Income Tax | 84,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Kura Oncology, Inc.'s stock has gained approximately 29.59427% over the past 52 weeks. The 50-day moving average sits at 11.19, while the 200-day moving average is 9.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | 29.59427% |
| 50-Day Moving Average | 11.19 |
| 200-Day Moving Average | 9.81 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kura Oncology, Inc. generated 77.23M in revenue and converted that into -296.77M in net income, yielding earnings per share of -3.36. EBITDA reached -316.80M, while operating income came in at -318.09M.
| Revenue | 77.23M |
| Gross Profit | 38.63M |
| Operating Income | -318.09M |
| Pretax Income | -296.69M |
| Net Income | -296.77M |
| EBITDA | -316.80M |
| EBIT | -318.09M |
| Earnings Per Share (EPS) | -3.36 |
Balance Sheet
Kura Oncology, Inc. holds 519.03M in cash and equivalents against 24.46M in total debt, resulting in a net debt position of -60.45M. Total book value stands at 48.43M, with working capital of 441.25M providing operational flexibility.
| Cash & Cash Equivalents | 519.03M |
| Total Debt | 24.46M |
| Net Debt | -60.45M |
| Equity (Book Value) | 48.43M |
| Book Value Per Share | 0.54 |
| Working Capital | 441.25M |
Cash Flow
Kura Oncology, Inc. produced -111.76M in operating cash flow over the past twelve months. After subtracting -5.67M in capital expenditures, free cash flow totaled -117.43M - equivalent to -1.33 per share.
| Operating Cash Flow | -111.76M |
| Capital Expenditures | -5.67M |
| Free Cash Flow | -117.43M |
| FCF Per Share | -1.33 |
Margins
Kura Oncology, Inc. operates with a gross margin of 99.35, reflecting its pricing power and cost economics. The operating margin of -411.90 and net profit margin of -384.30 provide insight into operational efficiency.
| Gross Margin | 99.35 |
| Operating Margin | -411.90 |
| Pretax Margin | -384.19 |
| Profit Margin | -384.30 |
| EBITDA Margin | -410.23 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.28 |
| FCF Yield | -10.95 |
Scores
Kura Oncology, Inc. posts an Altman Z-Score of -2.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.80 |